Owlet Résultats passés
Passé contrôle des critères 0/6
Owlet a connu une croissance annuelle moyenne de ses bénéfices de 13.3%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 14.8% par an. Les revenus ont augmenté de en hausse à un taux moyen de 4.7% par an.
Informations clés
13.27%
Taux de croissance des bénéfices
38.81%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 8.90% |
| Taux de croissance des recettes | 4.66% |
| Rendement des fonds propres | -135.99% |
| Marge nette | -44.60% |
| Prochaine mise à jour des résultats | 11 Aug 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jul 24
OWLT: Customer Adoption And Subscriptions Will Drive Future Upside Potential
Owlet's updated analyst price target shifts from $20 to $15 as analysts factor in revised growth expectations, slightly adjusted discount rates, and a lower future P/E multiple, while still highlighting the potential for upside from increased customer adoption and subscriptions. What’s in the News for Owlet Owlet, Inc.
Mise à jour du récit • Jul 10
OWLT: Guidance Reset And Subscriptions Are Expected To Drive Upside
Analysts have lowered their price target on Owlet stock from $13 to $10, reflecting a reset in expectations while still highlighting what they see as an underappreciated brand with potential for upside as customer adoption and subscription features develop. What’s in the News for Owlet Owlet, Inc.Seeking Alpha • Jul 08
Owlet: Changes Galore As Co-Founder Takes The Reins Once Again (Rating Upgrade)
Summary Owlet shifts strategy under returning CEO Workman, prioritizing subscriptions and telehealth over hardware for multi-year recurring revenue. OWLT narrows its geographic focus to the U.S. and Europe, exits low-margin Asian markets, and aims for profitability by leveraging AI-driven efficiencies. Q1 2026 revenue grew 6% to $23M, but operating losses widened; management lowered full-year revenue guidance but raised adjusted EBITDA outlook. Despite improved liquidity via a $25M credit facility and attractive valuation, I remain cautious given ongoing going concern risks and uncertain execution. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 26
OWLT: Guidance Reset And Adoption Initiatives Will Support Future Execution
Analysts have trimmed their fair value estimate for Owlet from $17.00 to $13.00, reflecting updated assumptions on growth, profitability, and P/E, while still pointing to potential upside supported by views that the recent guidance reset and improving hardware and subscription features could attract more customers over time. What's in the News for Owlet Owlet launched Dream Sight and Dream Duo 3 across Australia and New Zealand, bringing its full lineup of baby monitoring products, including Dream Sock, to those markets for the first time.Mise à jour du récit • Jun 04
OWLT: Softer Q1 Guide Seen Preceding Stronger 2026 Second Half
Narrative Update The analyst price target for Owlet has been reduced from $20 to $15, with analysts pointing to softer Q1 guidance, while also noting 2026 expectations that suggest a more robust back half of that year. What's in the News Owlet launched Dream Sight and Dream Duo 3 across Australia and New Zealand, expanding its full baby monitoring product lineup in those markets, including Dream Sock, Dream Sight, and Dream Duo 3.Mise à jour du récit • May 11
OWLT: Softer Q1 Outlook Seen Setting Up Stronger 2026 Finish
Analysts have trimmed their price target on Owlet stock to $15 from $20, citing Q1 guidance that came in below expectations, while highlighting that 2026 guidance still lines up with prior views and points to a potentially stronger second half of that year. Analyst Commentary Bearish analysts are signaling a more cautious stance on Owlet after recent guidance, using the reduced price target as a way to reset expectations while still acknowledging longer term potential.Mise à jour du récit • Apr 20
OWLT: Softer Q1 Outlook Expected To Set Up Stronger Second Half 2026
Analysts have lowered their price target on Owlet to $15 from $20, citing slightly softer Q1 guidance versus expectations. They also note that current management guidance indicates the second half of 2026 could be more robust.Mise à jour du récit • Apr 05
OWLT: Guidance And Partnerships Are Expected To Support A Stronger Second Half 2026
Analysts have revised Owlet's price target to $15, down from $19, reflecting mixed near term guidance and updated models that still indicate the possibility of stronger performance in the longer term. Analyst Commentary Recent research updates on Owlet point to a more cautious tone, even as some longer term expectations remain in place.Mise à jour du récit • Mar 22
OWLT: Updated Modeling And Healthcare Partnerships Will Support Stronger Second Half 2026
Analysts have updated their view on Owlet, trimming the consolidated price target to $15 as they factor in softer Q1 guidance, a higher assumed P/E multiple and lower projected revenue growth and profit margins, while still highlighting expectations for a stronger second half of 2026. Analyst Commentary Recent research highlights a more measured tone around Owlet, with some price targets recalibrated as analysts balance solid past execution with softer near term guidance and updated valuation assumptions.Mise à jour du récit • Mar 08
OWLT: Updated Modeling And New Healthcare Partnerships Will Support Future Upside Potential
Analysts have adjusted their outlook on Owlet, trimming the price target from $14 to $13 as they factor in updated expectations for growth, profitability, and future P/E assumptions that are informed by recent research highlighting mixed near term guidance alongside longer term projections that are described as steady. Analyst Commentary Recent Street research reflects a mixed but increasingly cautious tone around Owlet, with some bearish analysts trimming price targets as they reassess growth visibility and execution risk against current valuation.Mise à jour du récit • Feb 22
OWLT: Updated Modeling And FDA Pathways Will Support Future Upside Potential
Analysts have lifted their price target on Owlet to $19 from $15, citing updated modeling assumptions following a transfer of coverage. Analyst Commentary Recent research points to a reset in expectations around Owlet, with updated modeling used to support a US$19 price target.Mise à jour du récit • Feb 07
OWLT: Additional Liquidity And Partnerships Will Extend Funding Runway
Analysts have lifted their price target on Owlet to US$20 from US$15, citing updated models that factor in recent Street research highlighting a refreshed coverage framework and additional liquidity that supports the company’s plans. Analyst Commentary Bullish analysts are pointing to recent price target revisions as a sign of growing confidence in Owlet’s ability to execute on its plans, especially as fresh research coverage and additional liquidity are incorporated into updated models.Article d’analyse • Feb 05
Some Owlet, Inc. (NYSE:OWLT) Shareholders Look For Exit As Shares Take 31% Pounding
Owlet, Inc. ( NYSE:OWLT ) shares have retraced a considerable 31% in the last month, reversing a fair amount of their...Mise à jour du récit • Jan 24
OWLT: Liquidity And New Coverage Models Will Support Future Execution
Narrative Update: Owlet Analyst Price Target Shift Analysts have lifted their price target on Owlet from US$16 to US$17, reflecting updated models that factor in recent target increases on the Street and comfort with assumptions around fair value, discount rate, and a higher future P/E multiple. Analyst Commentary Recent Street research has tilted constructive on Owlet, with bullish analysts lifting price targets and updating their models following new company information and a transfer of coverage.Mise à jour du récit • Jan 09
OWLT: Liquidity And Regulatory Progress Will Support Execution While Risks Remain
Analysts have lifted their price target on Owlet to US$16.00 from US$14.88, citing refreshed models that factor in recent price target increases from firms updating coverage and highlighting added liquidity to support R&D into 2026. Analyst Commentary Recent Street research has trended constructive on Owlet, with higher price targets reflecting refreshed coverage models and a focus on liquidity and execution into 2026.Mise à jour du récit • Dec 15
OWLT: FDA Focus And Global Expansion Will Shape Balanced Risk Profile
Analysts have raised their fair value estimate for Owlet from $11.00 to $14.00 per share, citing stronger projected revenue growth, improved liquidity from a recent stock offering, and an FDA highlighted competitive moat that supports a higher long term price target. Analyst Commentary Recent research commentary has underscored a more constructive outlook on Owlet, with price targets moving higher following what was described as a solid quarter and improved balance sheet flexibility.Article d’analyse • Dec 05
There's Reason For Concern Over Owlet, Inc.'s (NYSE:OWLT) Massive 67% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 67% gain in the last month alone. The...Mise à jour du récit • Dec 01
OWLT: Regulatory Momentum And FDA Approval Will Drive Market Leadership Forward
Analysts have increased their price target for Owlet to $15.50 from $12.00, citing a solid quarter, improved liquidity, and the company's status as the only FDA-approved over-the-counter infant monitoring device as key drivers for their more favorable outlook. Analyst Commentary Recent analyst perspectives on Owlet reflect a mixed but largely positive sentiment following the company's most recent financial results and regulatory developments.Mise à jour du récit • Nov 17
OWLT: Regulatory Approvals And Increased Liquidity Will Support Long-Term Market Leadership
Analysts have raised their price target for Owlet from $13.20 to $14.83. They cite stronger revenue growth, improved profitability, and increased liquidity following the company's solid recent quarter.Article d’analyse • Oct 07
Further Upside For Owlet, Inc. (NYSE:OWLT) Shares Could Introduce Price Risks After 31% Bounce
Owlet, Inc. ( NYSE:OWLT ) shares have had a really impressive month, gaining 31% after a shaky period beforehand. The...Mise à jour du récit • Aug 09
Telehealth Partnerships And AI Insights Will Broaden Digital Health Markets
Driven by strong consumer demand for its FDA-cleared Dream Sock and a unique competitive position, analysts have raised Owlet’s price target from $12.30 to $13.20. Analyst Commentary The $300 Dream Sock is currently a best-selling smart baby monitor on Amazon, demonstrating strong consumer traction.Article d’analyse • Jun 14
Investors Still Aren't Entirely Convinced By Owlet, Inc.'s (NYSE:OWLT) Revenues Despite 34% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 34% gain in the last month alone. The last...
Nouveau récit • Apr 10
Dream Sock, BabySat, And Company360 Will Expand Global Healthcare Access
Owlet's FDA and CE approvals pave the way for global market expansion, boosting international revenue potential.Article d’analyse • Oct 18
Many Still Looking Away From Owlet, Inc. (NYSE:OWLT)
Owlet, Inc.'s ( NYSE:OWLT ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Owlet gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 107 | -48 | 50 | 15 |
| 31 Dec 25 | 106 | -42 | 48 | 14 |
| 30 Sep 25 | 100 | -42 | 50 | 13 |
| 30 Jun 25 | 90 | -52 | 50 | 12 |
| 31 Mar 25 | 84 | -17 | 49 | 10 |
| 31 Dec 24 | 78 | -17 | 48 | 10 |
| 30 Sep 24 | 79 | -11 | 43 | 10 |
| 30 Jun 24 | 66 | -11 | 40 | 9 |
| 31 Mar 24 | 58 | -19 | 39 | 10 |
| 31 Dec 23 | 54 | -33 | 41 | 10 |
| 30 Sep 23 | 45 | -49 | 50 | 13 |
| 30 Jun 23 | 53 | -61 | 60 | 17 |
| 31 Mar 23 | 58 | -63 | 70 | 22 |
| 31 Dec 22 | 69 | -79 | 80 | 28 |
| 30 Sep 22 | 55 | -84 | 75 | 31 |
| 30 Jun 22 | 69 | -99 | 78 | 30 |
| 31 Mar 22 | 75 | -93 | 74 | 27 |
| 31 Dec 21 | 76 | -72 | 64 | 21 |
| 30 Sep 21 | 99 | -53 | 60 | 17 |
| 30 Jun 21 | 89 | -20 | 46 | 14 |
| 31 Mar 21 | 82 | -16 | 38 | 11 |
| 31 Dec 20 | 75 | -11 | 32 | 10 |
| 31 Dec 19 | 50 | -18 | 29 | 11 |
Des revenus de qualité: OWLT n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: OWLT n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: OWLT n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 13.3% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de OWLT au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: OWLT n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Medical Equipment ( 14.8% ).
Rendement des fonds propres
ROE élevé: OWLT a un retour sur capitaux propres négatif ( -135.99% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/27 16:01 |
| Cours de l'action en fin de journée | 2026/07/24 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Owlet, Inc. est couverte par 8 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Allen Lutz | BofA Global Research |
| James Suva | Citigroup Inc |
| Ilya Zubkov | Freedom Broker |